TY - JOUR
T1 - EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel
AU - Babiloni, Claudio
AU - Arakaki, Xianghong
AU - Bonanni, Laura
AU - Bujan, Ana
AU - Carrillo, Maria C.
AU - del Percio, Claudio
AU - Edelmayer, Rebecca M.
AU - Egan, Gary
AU - Elahh, Fanny M.
AU - Evans, Alan
AU - Ferri, Raffaele
AU - Frisoni, Giovanni B.
AU - Güntekin, Bahar
AU - Hainsworth, Atticus
AU - Hampel, Harald
AU - Jelic, Vesna
AU - Jeong, Jaeseung
AU - Kim, Doh Kwan
AU - Kramberger, Milica
AU - Kumar, Sanjeev
AU - Lizio, Roberta
AU - Nobili, Flavio
AU - Noce, Giuseppe
AU - Puce, Aina
AU - Ritter, Petra
AU - Smit, Dirk J. A.
AU - Soricelli, Andrea
AU - Teipel, Stefan
AU - Tucci, Federico
AU - Sachdev, Perminder
AU - Valdes-Sosa, Mitchell
AU - Valdes-Sosa, Pedro
AU - Vergallo, Andrea
AU - Yener, G. rsev
N1 - Funding Information: The present Paper was facilitated by the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; https://action.alz.org/personifyebusiness/Membership/ISTAART/PIA.aspx), through the Electrophysiology Professional Interest Area (PIA) and the Vascular Cognitive Disorders PIA (VCDPIA). The EPIA and VCDPIA are committed to exploit biomarkers for (1) improving the understanding of neurophysiological and neurovascular mechanisms underlying Alzheimer's and Cerebrovascular diseases and age-related dementing disorders at micro, meso, and macro spatial scale and (2) promoting clinical applications and international initiatives. Furthermore, this manuscript was endorsed by the Global Brain Consortium (https://globalbrainconsortium.org). The Global Brain Consortium is committed to achieving the vision of improved and more equitable health outcomes worldwide by strengthening linkages between neuroscientists across borders and disciplines. Quantitative EEG techniques and biomarkers are considered as an important resource for brain research and clinical applications in neurologic and psychiatric diseases, especially in lower- and middle-income countries. The Authors thank Dr. Keith N. Fargo for his helpful comments on a previous version of this manuscript. Funding Information: No relevant conflict of interest for the co-Authors in the present article. Dr. Claudio Babiloni is supported by European Committee (H2020-EU.1.3.1.H2020-MSCA-ITN-ETN-2016 project with short title “BBDiag”). Dr. Flavio Nobili: This work was developed within the framework of the DINOGMI Department of Excellence of MIUR 2018-2022 (legge 232 del 2016). Dr. Petra Ritter is supported by H2020 Research and Innovation Action grants VirtualBrainCloud 826421, Human Brain Project 785907, 945539 and ERC 683049; German Research Foundation CRC 1315, CRC 936, and RI 2073/6-1; Berlin Institute of Health & Foundation Charité, Johanna Quandt Excellence Initiative. Dr. Harald Hampel is an employee of Eisai Inc., serves as Senior Associate Editor for the Journal Alzheimer's & Dementia. Before May 2019, he had received lecture fees, travel funding, and research grants from several Pharmacological Companies but irrelevant for the aim of this manuscript. His contribution to this article reflects entirely and only his own academic expertise on the matter. Dr. Maria C. Carrillo, Dr. Rebecca M. Edelmayer are full-time employees of the Alzheimer's Association. Dr. Keith Fargo was a former full-time employee of the Alzheimer's Association during drafting of the manuscript, but now he is the CSO of the CMT Research Foundation. Dr. Andrea Vergallo is an employee of Eisai Inc. He does not receive any fees or honoraria since November 2019. Before November 2019 he had received lecture honoraria from Roche, MagQu LLC, and Servier but irrelevant for the aim of this manuscript. His contribution to this article reflects entirely and only his own academic expertise on the matter. Publisher Copyright: © 2021 Elsevier Inc. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Vascular contribution to cognitive impairment (VCI) and dementia is related to etiologies that may affect the neurophysiological mechanisms regulating brain arousal and generating electroencephalographic (EEG) activity. A multidisciplinary expert panel reviewed the clinical literature and reached consensus about the EEG measures consistently found as abnormal in VCI patients with dementia. As compared to cognitively unimpaired individuals, those VCI patients showed (1) smaller amplitude of resting state alpha (8–12 Hz) rhythms dominant in posterior regions; (2) widespread increases in amplitude of delta (< 4 Hz) and theta (4–8 Hz) rhythms; and (3) delayed N200/P300 peak latencies in averaged event-related potentials, especially during the detection of auditory rare target stimuli requiring participants’ responses in “oddball” paradigms. The expert panel formulated the following recommendations: (1) the above EEG measures are not specific for VCI and should not be used for its diagnosis; (2) they may be considered as “neural synchronization” biomarkers to enlighten the relationships between features of the VCI-related cerebrovascular lesions and abnormalities in neurophysiological brain mechanisms; and (3) they may be tested in future clinical trials as prognostic biomarkers and endpoints of interventions aimed at normalizing background brain excitability and vigilance in wakefulness.
AB - Vascular contribution to cognitive impairment (VCI) and dementia is related to etiologies that may affect the neurophysiological mechanisms regulating brain arousal and generating electroencephalographic (EEG) activity. A multidisciplinary expert panel reviewed the clinical literature and reached consensus about the EEG measures consistently found as abnormal in VCI patients with dementia. As compared to cognitively unimpaired individuals, those VCI patients showed (1) smaller amplitude of resting state alpha (8–12 Hz) rhythms dominant in posterior regions; (2) widespread increases in amplitude of delta (< 4 Hz) and theta (4–8 Hz) rhythms; and (3) delayed N200/P300 peak latencies in averaged event-related potentials, especially during the detection of auditory rare target stimuli requiring participants’ responses in “oddball” paradigms. The expert panel formulated the following recommendations: (1) the above EEG measures are not specific for VCI and should not be used for its diagnosis; (2) they may be considered as “neural synchronization” biomarkers to enlighten the relationships between features of the VCI-related cerebrovascular lesions and abnormalities in neurophysiological brain mechanisms; and (3) they may be tested in future clinical trials as prognostic biomarkers and endpoints of interventions aimed at normalizing background brain excitability and vigilance in wakefulness.
KW - Cerebrovascular disease (CVD)
KW - Event-related oscillations (EROs)
KW - Event-related potentials (ERPs)
KW - Resting state electroencephalographic (rsEEG) rhythms
KW - Small vessel disease
KW - Subcortical ischemic vascular disease
KW - Vascular cognitive impairment (VCI)
KW - Vascular contribution to cognitive impairment and dementia (VCID)
KW - Vascular dementia (VaD)
UR - http://www.scopus.com/inward/record.url?scp=85103754690&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.neurobiolaging.2021.03.003
DO - https://doi.org/10.1016/j.neurobiolaging.2021.03.003
M3 - Review article
C2 - 33845399
SN - 0197-4580
VL - 103
SP - 78
EP - 97
JO - Neurobiology of aging
JF - Neurobiology of aging
ER -